ClinicalTrials.gg

Program

TL-925

A development code.

Its studies are mostly in Conjunctivitis, Allergic · Dry Eye Syndromes, led by Telios Pharma.

Furthest: phase 2, since Feb 7, 20237 company-led studies, 5 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Telios Pharma75 open or runningphase 2since Feb 7, 2023Feb 7, 2023Mar 2027phase 2 · NCT07938632

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 7, 2023First study: phase 2 study in Dry Eye SyndromesFirst studyNCT05745064 · 107 enrolled · United States
  2. Oct 10, 2023Phase 2 study in Conjunctivitis, AllergicNCT06153342 · 70 planned · United States
  3. Jan 17, 2024Phase 2 study in Dry Eye SyndromesNCT06225973 · 880 enrolled · United States
  4. Feb 27, 2024Phase 2 study in Conjunctivitis, AllergicNCT06293820 · 80 enrolled · United States
  5. Nov 11, 2024Phase 2 study in Conjunctivitis, AllergicNCT06686472 · 66 planned · United States
  6. Oct 21, 2025Phase 2 study in Conjunctivitis, AllergicNCT07220408 · 60 planned · United States
  7. Nov 6, 2026Phase 2 study in Allergic Conjunctivitis of Both EyesNCT07938632 · 100 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 2 study in Allergic Conjunctivitis of Both EyesNCT07938632

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07938632Allergic Conjunctivitis of Both Eyes · United States2Not yet recruitingMar 2027100
NCT07220408Conjunctivitis, Allergic · United States2RecruitingFeb 202660
NCT06686472Conjunctivitis, Allergic · United States2RecruitingDec 10, 202466
NCT06293820Conjunctivitis, Allergic · United States2CompletedMay 21, 202480
NCT06225973Dry Eye Syndromes · United States2Active, not recruitingDec 2024880
NCT06153342Conjunctivitis, Allergic · United States2RecruitingJan 202470
NCT05745064Dry Eye Syndromes · United States2CompletedJul 11, 2023107

How it is read

Names in the registry

  • “TL-925”, 7 entries

Codes read as this program: TL925.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.